Pangaea Data

Pangaea Data is an AI-driven healthcare technology company focused on identifying untreated and under-treated patients at scale, improving patient outcomes across a wide range of disease areas. Through its flagship PALLUX platform, Pangaea Data helps pharmaceutical companies, healthcare systems, and clinical research organizations find patients who remain undiagnosed or misdiagnosed despite the availability of relevant intelligence within existing patient records.

The company serves life sciences organizations and healthcare providers seeking to close care gaps in both prevalent and rare, hard-to-diagnose conditions — including oncology, respiratory disease, rare metabolic disorders, cardiovascular conditions, autoimmune diseases, and more. Pangaea Data has established strategic partnerships and collaborations with leading organizations including AstraZeneca, Alexion, Microsoft, NVIDIA, and Topcon Healthcare, and its platform has been adopted by institutions such as the University of Illinois Cancer Center.

The PALLUX Platform

• PALLUX is Pangaea Data's core AI platform designed to find untreated and under-treated patients by processing existing patient records using reasoning based on established clinical guidelines, mimicking a clinician's manual review process.
• The platform delivers an intuitive, explainable dashboard that integrates directly into existing Electronic Health Record (EHR) systems, enabling clinicians to act on AI-generated insights without disrupting current workflows.
• PALLUX is applicable to both prevalent conditions and rare, hard-to-diagnose diseases, offering scalability across therapeutic areas and enabling opportunities for academic publication of findings.
• Deployment is designed to be low-friction, completing within 8 to 12 weeks using existing infrastructure with zero disruption to clinical or IT workflows.
• The platform is compliant with healthcare regulations, does not involve the transaction of patient data, and is not classified as Software as a Medical Device (SaMD), making it safe to deploy across healthcare settings.
• PALLUX has published superior performance compared to alternative pre-emptive and metadata-based patient identification approaches.

Disease Areas and Demonstrated Impact

• PALLUX has demonstrated the ability to identify significantly more patients across a broad range of conditions, including finding 5x more COPD patients, 2x more CKD patients, 6x more cancer cachexia patients, 1.3x more lung cancer patients, 1.4x more ovarian cancer patients, 1.7x more Crohn's disease patients, 1.4x more primary biliary cholangitis (PBC) patients, and previously unidentified lupus nephritis patients.
• The platform addresses conditions with high rates of underdiagnosis, including: 90% of CKD patients undiagnosed, 85% of hypertrophic cardiomyopathy patients undiagnosed, 73% of asthma patients undiagnosed, 70% of ovarian cancer patients experiencing diagnostic delays, 70% of lupus patients potentially misdiagnosed first, 66% of major depressive disorder patients misdiagnosed, 57% of ATTR amyloidosis patients undiagnosed, 50% of COPD patients undiagnosed, 50% of Marfan syndrome patients undiagnosed, 50% of primary biliary cholangitis patients potentially undiagnosed, 50% of cancer cachexia symptoms missed, and 38% of lung cancer patients undiagnosed.

Key Partnerships, Collaborations, and Notable Achievements

• Pangaea Data has entered an AI collaboration with Alexion to develop an AI-powered Clinical Decision Support System (AI-CDSS) aimed at improving the detection of Hypophosphatasia (HPP) in adults.
• The company has partnered with AstraZeneca to advance AI-powered precision healthcare.
• Pangaea Data and Microsoft have collaborated to integrate ambient listening and real-time AI insights into clinical workflows, combining PALLUX capabilities with Microsoft Dragon Copilot to enable clinicians to ambiently document consultations and receive actionable insights.
• Topcon Healthcare has made a strategic investment in Pangaea Data to support closing care gaps in eye care.
• The University of Illinois Cancer Center has adopted Pangaea's AI platform to uncover social determinants of health, with the platform demonstrating 94.7% accuracy in identifying 18 social drivers of health.
• Pangaea Data has been featured in a Microsoft and NVIDIA documentary highlighting its work in closing care gaps.

By combining clinical guideline-based AI reasoning with seamless EHR integration and a strong compliance posture, Pangaea Data enables life sciences and healthcare organizations to systematically surface patients who would otherwise remain undiagnosed, accelerating access to appropriate therapies, clinical trials, and drug discovery studies at scale.